Uveal melanoma (UM), a rare cancer originating from uveal tract melanocytes, exhibits four distinct molecular subsets. We conducted comprehensive multi-omics analysis comparing aggressive UM patient-derived xenograft models with normal melanocytes. Our findings highlight genomic instability as a UM hallmark. A recurrent BAP1 promoter deletion, linked to metastasis risk, was identified. Hi-C analysis unveiled chromatin topology changes linked to PRAME upregulation, an independent UM prognostic biomarker and potential therapeutic target. Our study showcases multi-omics’ role in elucidating UM tumorigenesis, revealing two distinct gene expression dysregulation mechanisms within this rare cancer.
Related Posts
Thriving Together: Valuing Every Unique Mind
In a diverse world, understanding and compassion are the cornerstones of inclusivity. Embracing individuals with varying mental abilities fosters a society that values every unique mind. Whether it’s autism, ADHD, or other cognitive differences, empathy paves the way for acceptance and support. By listening, learning, and adapting, we create environments where everyone can thrive. Together, […]
Revolutionizing Dermatology: 3D-Printed Skin with Hair Follicles
Scientists use 3D bioprinting to create lab-grown skin with embedded hair follicles. They develop bio-ink composed of cells and supportive materials mimicking skin structures. Printing precise follicle arrangements allows the formation of functional skin grafts, aiding wound healing and cosmetic applications. This technique also facilitates drug testing on skin models, offering insights into skin biology […]
Papillary Thyroid Carcinoma: Unraveling Mutational Complexity through NGS Analysis
In this study of 130 patients with classical papillary thyroid carcinoma (PTC), Next-Generation Sequencing (NGS) was utilized, revealing a high BRAF V600E mutation frequency (83.1%) attributed to Hokkaido’s high iodine intake from seaweed consumption. Unlike previous findings, direct correlation between BRAF V600E mutation and aggressive clinicopathologic features wasn’t established. However, co-existing mutations, notably with PIK3CA, […]